We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Cobra Biologics’ Expansion Continues

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cobra Biologics’ Expansion Continues"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Cobra Biologics has announced the appointment of three non-executive directors to Cobra Biologics’ board, and two business development managers tasked with driving continued growth in Europe and North America.

As part of Cobra Biologics’ strategy for sustained expansion, the Group has increased the size of its business development team with the appointment of Sharon Brownlow and Patrick Lansky.

Sharon was previously UK Sales and Marketing Manager for market-leading independent bioreactor manufacturer, Applikon Biotechnology.

She brings 15 years of experience in up and downstream processing sales and a strong scientific background in protein biochemistry.

Patrick has worked in the biotech industry for the last 16 years. He started his career working with Idec Pharmaceuticals and has spent the last 11 years working in sales, with the four of those years in the CMO business.

The appointment of three non-executive directors, Elisabeth Lindner, Professor Carl Johan Sundberg and Jinyue Wang, further reinforces the business acumen across the Cobra Biologics’ board.

They provide a wealth of both local and international technical and commercial expertise that will be invaluable in facilitating the expanding business.

Biographies of the Non-Executive Directors:

Elisabeth Lindner (MSc, MBA) lives in Stockholm, Sweden and is a member of the Royal Swedish Academy of Engineering Sciences. In addition to being a Cobra Biologics board member, she is Chairman and CEO of Biosource Europe AB and a board member of BioInvent International AB, KaroBio AB and Pharmalink AB. Elisabeth has significant senior management experience with Pharmacia Corporation, Octapharma AB and Diamyd Medical AB.

Professor Carl Johan Sundberg (MD, PhD) is a licensed physician and associate professor at the Department of Physiology & Pharmacology at Karolinska Institute in Stockholm, Sweden. Carl Johan co-founded the Karolinska Investment Fund, a €60m biomedical VC fund where he worked from 1999 to 2009 as investment manager. He also heads the Unit for Bio-entrepreneurship at Karolinska Institute and is a member of the International Olympic Committee´s Medical Commission, vice-president of Euroscience, and elected member of the Royal Swedish Academy of Engineering Sciences (IVA). Additionally, Carl Johan has also served as a member and or chairman of a plethora of academic and industry boards.

Jinyue Wang (MSc) lives in Beijing, China where he is the founder and managing Partner of 3N Partners - an investment partnership which is focused on life- science/clean-tech VC investment - as well as a specialist M&A advisor to the pharmaceutical sector. Prior to his current role, he founded and headed DSM Venturing in China. Jinyue brings considerable experience of the Chinese healthcare industry having worked for Roche, DSM and the Chinese central government since 1996. During his career he has reviewed more than 800 deals, completed more than 50 due diligences and closed 12 deals.

Peter Coleman CEO of Cobra Biologics said “The appointment of two business development managers and three non-executive directors highlights our ambitions to expand and develop Cobra Biologics. I am delighted that they have decided to join Cobra Biologics. I am sure that each one will provide the existing Cobra team with a ready source of technical and commercial experience and expertise as we grow Cobra Biologics. I look forward to working with them to achieve our ambitious goals.”